

January 30, 2025

| | |
|---|--|
| BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172 | National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051, India. Trading symbol: INDGN |
|---|--|

Dear Sir / Madam,

Sub: Intimation of outcome of Board Meeting

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of Indegene Limited at its meeting held today, i.e., January 30, 2025, has approved the following:

1. The unaudited consolidated financial results of the Company and its subsidiaries as per Indian Accounting Standards (INDAS) for the quarter December 31 ,2024 along with the limited review report of the Auditors thereon.
2. The unaudited standalone financial results of the Company as per INDAS for the quarter December 31,2024 along with the limited review report of the Auditors thereon.
3. To allot shares under ESOP 2020 plan & RSU 2020 plan

The meeting of the Board of Directors commenced at 1547 hours and concluded at 1700 hours.

The above information is being made available on the website of the Company.

<https://www.indegene.com/>

This is for your information and records.

Yours Sincerely,
For Indegene Limited

Srishti Ramesh Kaushik
Company Secretary and Compliance officer



Indegene Limited (Formerly Indegene Private Limited),
Third Floor, Aspen G-4 Block, Manyata Embassy
Business Park (SEZ), Outer Ring Road, Nagawara,
Bengaluru- 560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777
www.indegene.com

CIN: U73100KA1998PLC102040

Limited Review Report on unaudited consolidated financial results of Indegene Limited (formerly known as Indegene Private Limited) for the quarter ended 31 December 2024 and year to date results for the period from 1 April 2024 to 31 December 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Indegene Limited (formerly known as Indegene Private Limited)

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Indegene Limited (formerly known as Indegene Private Limited) (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 31 December 2024 and year to date results for the period from 1 April 2024 to 31 December 2024 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "*Review of Interim Financial Information Performed by the Independent Auditor of the Entity*", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement.
5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Limited Review Report (Continued)

Indegene Limited (formerly known as Indegene Private Limited)

6. We did not review the interim financial information of 5 step subsidiaries included in the Statement, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 1,190 million and Rs. 3,495 million, total net profit after tax (before consolidation adjustments) of Rs. 128 million and Rs. 345 million and total comprehensive income (before consolidation adjustments) of Rs. 129 million and Rs. 350 million, for the quarter ended 31 December 2024 and year to date results for the period from 1 April 2024 to 31 December 2024 respectively, as considered in the Statement. The interim financial information of these step subsidiaries have been reviewed by other auditors whose reports have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these step subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion is not modified in respect of this matter.

7. The Statement includes the interim financial information of 3 subsidiaries and 6 step subsidiaries which have not been reviewed, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 243 million and Rs. 716 million, total net loss after tax (before consolidation adjustments) of Rs. 108 million and Rs. 113 million and total comprehensive loss (before consolidation adjustments) of Rs. 190 million and Rs. 145 million, for the quarter ended 31 December 2024 and year to date results for the period from 1 April 2024 to 31 December 2024 respectively, as considered in the Statement. According to the information and explanations given to us by the Parent's management, the interim financial information of these subsidiaries and step subsidiaries are not material to the Group.

Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Vikash Gupta

Partner

Bangalore

30 January 2025

Membership No.: 064597

UDIN:25064597BMOXQZ1991

Limited Review Report (Continued)
Indegene Limited (formerly known as Indegene Private Limited)

Annexure I

The unaudited consolidated financial results include financial results of the Holding Company and entities listed below:

| Sr. No | Name of component | Relationship | Country of Incorporation |
|--------|--|--|--------------------------|
| 1 | ILSL Holdings Inc. | Subsidiary | USA |
| 2 | Indegene Japan LLC | Subsidiary | Japan |
| 3 | Indegene Healthcare Mexico S DE RL DE CV | Subsidiary | Mexico |
| 4 | Indegene Ireland Limited | Subsidiary (w.e.f. 30 June 2023) Step-Subsidiary (upto 29 June 2023) | Ireland |
| 5 | Indegene Inc. | Step subsidiary | USA |
| 6 | Services Indegene Aptilon Inc. | Step subsidiary | Canada |
| 7 | DT Associates Research and Consulting Services Limited | Step subsidiary | England |
| 8 | Cult Health LLC | Step subsidiary | USA |
| 9 | Indegene Healthcare Germany GmbH | Step subsidiary | Germany |
| 10 | DT Associates Research and Consulting Inc. | Step subsidiary | USA |
| 11 | Indegene Fareast Pte. Ltd. | Step subsidiary (w.e.f. 28 December 2023) Subsidiary (upto 27 December 2023) | Singapore |
| 12 | Indegene Europe LLC | Step subsidiary (w.e.f. 27 December 2023) Subsidiary (upto 26 December 2023) | Switzerland |
| 13 | Indegene Lifesystems Consulting (Shanghai) Co. Ltd. | Step subsidiary (w.e.f. 29 February 2024) Subsidiary (upto 28 February 2024) | China |
| 14 | Indegene Healthcare UK Limited | Step subsidiary (w.e.f. 07 December 2023) | England |

V4

Limited Review Report (Continued)

Indegene Limited (formerly known as Indegene Private Limited)

| Sr. No | Name of component | Relationship | Country of Incorporation |
|--------|--------------------------------------|--|--------------------------|
| 15 | Trilogy Writing & Consulting GmbH | Step subsidiary (w.e.f. 22 March 2024) | Germany |
| 16 | Trilogy Writing & Consulting Limited | Step subsidiary (w.e.f. 22 March 2024) | England |
| 17 | Trilogy Writing & Consulting Inc. | Step subsidiary (w.e.f. 22 March 2024) | USA |
| 18 | Trilogy Writing & Consulting ULC | Step subsidiary (w.e.f. 22 March 2024) | Canada |
| 19 | Indegene Spain, S.L.U. | Step subsidiary (w.e.f. 12 November 2024) | Spain |


Vh

(All amounts in ₹ millions, except share data and where otherwise stated)

| Sl. No. | Particulars | Quarter ended | | | Nine months ended | | Year ended |
|---------|--|------------------|-------------------|------------------|-------------------|------------------|---------------|
| | | 31 December 2024 | 30 September 2024 | 31 December 2023 | 31 December 2024 | 31 December 2023 | 31 March 2024 |
| | | Unaudited | Unaudited | Unaudited | Unaudited | Audited | Audited |
| 1 | Income | | | | | | |
| | (a) Revenue from operations | 7,204 | 6,868 | 6,734 | 20,837 | 19,166 | 25,896 |
| | (b) Other income (net) | 377 | 214 | 131 | 816 | 531 | 763 |
| | Total income | 7,581 | 7,082 | 6,865 | 21,653 | 19,697 | 26,659 |
| 2 | Expenses | | | | | | |
| | (a) Employee benefits expense | 4,438 | 4,420 | 4,131 | 13,301 | 12,232 | 16,516 |
| | (b) Finance costs | 32 | 40 | 121 | 189 | 371 | 494 |
| | (c) Depreciation and amortisation expense | 200 | 194 | 176 | 595 | 576 | 761 |
| | (d) Other expenses | 1,448 | 1,187 | 1,114 | 3,668 | 3,267 | 4,326 |
| | Total expenses | 6,118 | 5,841 | 5,542 | 17,753 | 16,446 | 22,097 |
| 3 | Profit before exceptional item and tax (1-2) | 1,463 | 1,241 | 1,323 | 3,900 | 3,251 | 4,562 |
| 4 | Exceptional items (net) (refer note 5) | - | - | - | - | - | 24 |
| 5 | Profit before tax (3+4) | 1,463 | 1,241 | 1,323 | 3,900 | 3,251 | 4,586 |
| 6 | Tax expense | | | | | | |
| | - Current tax | 338 | 363 | 632 | 1,053 | 1,124 | 1,255 |
| | - Deferred tax | 28 | (39) | (297) | (44) | (292) | (36) |
| | Total Tax Expense | 366 | 324 | 335 | 1,009 | 832 | 1,219 |
| 7 | Profit for the period / year (5-6) | 1,097 | 917 | 988 | 2,891 | 2,419 | 3,367 |
| 8 | Other Comprehensive Income (OCI), net of taxes | | | | | | |
| | <i>Items that will not be reclassified subsequently to the statement of profit or loss:</i> | | | | | | |
| | Remeasurement of defined benefit obligation | 11 | (8) | (15) | 18 | 2 | ^ |
| | Income tax impact | (3) | 2 | 4 | (5) | (1) | ^ |
| | <i>Items that will be reclassified subsequently to profit or loss:</i> | | | | | | |
| | Exchange differences on translating the financial statements of foreign operations | 124 | 112 | 7 | 217 | 60 | 79 |
| | Total Other Comprehensive (Loss)/Income for the period/year (net of tax) | 132 | 106 | (4) | 230 | 61 | 79 |
| 9 | Total comprehensive income for the period / year (7+8) | 1,229 | 1,023 | 984 | 3,121 | 2,480 | 3,446 |
| | Profit for the period / year attributable to: | | | | | | |
| | Owners of the Parent | 1,097 | 917 | 988 | 2,891 | 2,419 | 3,367 |
| | Other Comprehensive (Loss)/Income for the period / year attributable to: | | | | | | |
| | Owners of the Parent | 132 | 106 | (4) | 230 | 61 | 79 |
| | Total comprehensive income for the period / year attributable to Owners of the Parent | 1,229 | 1,023 | 984 | 3,121 | 2,480 | 3,446 |
| 10 | Paid-up equity share capital (Face value of ₹ 2 each) | 478 | 478 | 444 | 478 | 444 | 444 |
| 11 | Other equity | | | | | | 13,847 |
| 12 | Earnings per equity share (face value of ₹ 2 each)* | | | | | | |
| | (a) Basic (in ₹) | 4.59 | 3.84 | 4.45 | 12.23 | 10.91 | 15.19 |
| | (b) Diluted (in ₹) | 4.55 | 3.80 | 4.42 | 12.12 | 10.84 | 15.07 |

* EPS is not annualized for the quarter and nine months period ended.

See accompanying notes to the Consolidated Financial Results




(All amounts in ₹ millions, except share data and where otherwise stated)

1. The above Consolidated Financial Results of the Group have been prepared in accordance with Indian Accounting Standards ("Ind AS") 34 - Interim Financial Reporting, recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the regulations"). Due to rounding off, the numbers presented throughout may not add up precisely to the totals. "^^" in the financial information denote amounts less than ₹ 0.50 million.
2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 30 January 2025. The statutory auditors have performed a limited review of the Consolidated Financial Results for the quarter and nine months ended 31 December 2024 and have issued an unmodified review report on the same.
3. The Consolidated Financial Results for the quarter and nine months ended 31 December 2024, are available on the National Stock Exchange of India Limited (URL: www.nseindia.com), the BSE Limited website (URL: www.bseindia.com) and on the Company's website (URL: www.indegene.com/investor-relations).
4. During the nine months ended 31 December 2024, the Company has completed Initial Public Offer (IPO) of 40,766,550 equity shares of face value of ₹2 each at an issue price of ₹452 per share, comprising fresh issue of 16,833,818 shares aggregating to ₹7,600 and offer for sale of 23,932,732 shares by selling shareholders aggregating to ₹10,818. The Equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 13 May 2024. The Company was not mandatorily required to prepare and publish results for the quarter and nine months ended 31 December 2023 in accordance with the regulations.
5. Exceptional items:
On 12 October 2022, the Group had obtained control of Cult Health LLC by acquiring 100% interest to enhance the Group's commercialization portfolio adding market development and brand strategy competencies along with patient engagement platforms. The acquisition was consummated for a consideration of ₹ 5,347. The contingent consideration is based on the performance of Cult during the fiscal year beginning 01 April 2023 and ending 31 March 2026 and range of contingent consideration payable is between ₹ Nil to ₹ 3,040. Cult Health LLC is part of Omnichannel Activation segment.

The Group carried out remeasurement of the change in fair value of contingent consideration towards earnout payout, which was measured at its fair value on acquisition and recognised a resultant gain of ₹935. Change in fair value movement of contingent consideration has been recognized as an exceptional item during the year ended 31 March 2024. Further, the Group also carried out the assessment of recoverable value of the investments made in Cult Health LLC owing to reduction in revenues from certain customers and its impact on the future cash flows. The recoverable amount of this CGU estimated to be lower than carrying value, resulting into an impairment charge of ₹ 911. The impairment charge had been recognized as an exceptional item during the year ended 31 March 2024.
6. Basis the Management's assessment/ remeasurement of the fair value of the contingent consideration payable, the Group has reversed contingent consideration pertaining to acquisition of Cult Health LLC and Trilogy Writing & Consulting GmbH ("Trilogy") amounting to ₹ 103 and ₹ 55, respectively and has been accounted for the same as other income during the quarter and nine months ended 31 December 2024. Further, the Group had invested in TriloDocs GmbH at the time of acquisition of Trilogy via convertible loan of EUR 1.5 Mn. Based on assessment of recoverability of the loan given to TriloDocs GmbH aggregating to ₹ 136, the Group has fully provided for the same during the quarter and nine months ended 31 December 2024 and accounted it as other expenses.

(This space has been intentionally left blank)



(All amounts in ₹ millions, except share data and where otherwise stated)

7. The Segment results of the Group has been prepared in accordance with Ind-AS 108 on "Operating Segments". The Group has identified business segments (industry practice) as reportable segments. The business segments comprise: 1) Enterprise Medical Solutions, 2) Enterprise Commercial Solutions, 3) Omnichannel Activation.

Segment wise revenue and results are as follows:

| Particulars | Quarter ended | | | Nine months ended | | Year ended |
|---------------------------------------|---------------|--------------|--------------|-------------------|---------------|---------------|
| | 31 December | 30 September | 31 December | 31 December | 31 December | 31 March |
| | 2024 | 2024 | 2023 | 2024 | 2023 | 2024 |
| | Unaudited | Unaudited | Unaudited | Unaudited | Audited | Audited |
| 1. Segment revenue | | | | | | |
| Enterprise Medical Solutions | 2,052 | 1,977 | 1,521 | 5,918 | 4,406 | 6,008 |
| Enterprise Commercial Solutions | 4,003 | 3,863 | 3,899 | 11,615 | 11,360 | 15,287 |
| Omnichannel Activation | 889 | 798 | 920 | 2,510 | 2,312 | 3,191 |
| Others* | 260 | 230 | 394 | 794 | 1,088 | 1,410 |
| Total | 7,204 | 6,868 | 6,734 | 20,837 | 19,166 | 25,896 |
| 2. Segment results | | | | | | |
| Enterprise Medical Solutions | 534 | 521 | 459 | 1,496 | 1,204 | 1,679 |
| Enterprise Commercial Solutions | 903 | 797 | 977 | 2,569 | 2,637 | 3,627 |
| Omnichannel Activation | 132 | 90 | 170 | 311 | 164 | 256 |
| Others* | (62) | (95) | (26) | (229) | (149) | (213) |
| Total | 1,507 | 1,313 | 1,580 | 4,147 | 3,856 | 5,349 |
| Unallocable expenses | (189) | (52) | (91) | (279) | (189) | (295) |
| Depreciation and amortisation expense | (200) | (194) | (176) | (595) | (576) | (761) |
| Other income (net) | 377 | 214 | 131 | 816 | 531 | 763 |
| Finance cost | (32) | (40) | (121) | (189) | (371) | (494) |
| Exceptional items | - | - | - | - | - | 24 |
| Tax expense | (366) | (324) | (335) | (1,009) | (832) | (1,219) |
| Profit after Tax | 1,097 | 917 | 988 | 2,891 | 2,419 | 3,367 |

*Others mainly comprises of consultancy and clinical business.

Notes on Segment information

Operating segments are identified as components of an enterprise for which discrete financials information is available that is evaluated regularly by the chief operating decision maker. In deciding how to allocate resources and assessing performance, the Group's chief operating decision maker is the Chief Executive Officer and Executive Director.

Assets and liabilities used in the Group's business are not identified to any of the operating segments, as these are used interchangeably between segments. Management believes that it is currently not practicable to provide segment disclosures relating to total assets and liabilities since a meaningful segregation of the available data is onerous.

Bengaluru
30 January 2025



by Order of the Board of
INDEGENE LIMITED
(formerly INDEGENE PRIVATE LIMITED)

Manish Gupta
Chief Executive Officer and Executive Director

B S R & Co. LLP

Chartered Accountants

Embassy Golf Links Business Park
Pebble Beach, B Block, 3rd Floor
No. 13/2, off Intermediate Ring Road
Bengaluru - 560 071, India
Telephone: +91 80 4682 3000
Fax: +91 80 4682 3999

Limited Review Report on unaudited standalone financial results of Indegene Limited (formerly known as Indegene Private Limited) for the quarter ended 31 December 2024 and year to date results for the period from 1 April 2024 to 31 December 2024 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Indegene Limited (formerly known as Indegene Private Limited)

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Indegene Limited (formerly known as Indegene Private Limited) (hereinafter referred to as "the Company") for the quarter ended 31 December 2024 and year to date results for the period from 1 April 2024 to 31 December 2024 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Co. LLP

Chartered Accountants

Firm's Registration No.:101248W/W-100022



Vikash Gupta

Partner

Membership No.: 064597

UDIN:25064597BMOXQY6908

Bangalore

30 January 2025

Registered Office

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

Page 1 of 2

Indegene Limited (formerly Indegene Private Limited)

CIN No. U73100KA1998PLC102040

Statement of Standalone Financial Results for the quarter and nine months ended 31 December 2024

(All amounts in ₹ millions, except share data and where otherwise stated)

| Sl. No. | Particulars | Quarter ended | | | Nine months ended | | Year ended |
|---------|---|---------------|--------------|--------------|-------------------|--------------|---------------|
| | | 31 December | 30 September | 31 December | 31 December | 31 December | 31 March |
| | | 2024 | 2024 | 2023 | 2024 | 2023 | 2024 |
| | | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| 1 | Income | | | | | | |
| | (a) Revenue from operations | 2,867 | 2,817 | 2,600 | 8,269 | 7,731 | 10,456 |
| | (b) Other income (net) | 223 | 224 | 120 | 551 | 272 | 503 |
| | Total income | 3,090 | 3,041 | 2,720 | 8,820 | 8,003 | 10,959 |
| 2 | Expenses | | | | | | |
| | (a) Employee benefits expense | 1,922 | 1,971 | 1,879 | 5,747 | 5,574 | 7,523 |
| | (b) Finance costs | 16 | 16 | 17 | 47 | 51 | 66 |
| | (c) Depreciation and amortisation expense | 65 | 62 | 65 | 193 | 235 | 311 |
| | (d) Other expenses | 426 | 382 | 351 | 1,113 | 941 | 1,253 |
| | Total expenses | 2,429 | 2,431 | 2,312 | 7,100 | 6,801 | 9,153 |
| 3 | Profit before tax (1-2) | 661 | 610 | 408 | 1,720 | 1,202 | 1,806 |
| 4 | Tax expense | | | | | | |
| | - Current tax | 169 | 168 | 116 | 456 | 322 | 443 |
| | - Deferred tax | (7) | (6) | (4) | (6) | (10) | (16) |
| | Total tax expense | 162 | 162 | 112 | 450 | 312 | 427 |
| 5 | Profit for the period/year (3-4) | 499 | 448 | 296 | 1,270 | 890 | 1,379 |
| 6 | Other Comprehensive Income (OCI), net of taxes | | | | | | |
| | <i>Items that will not be reclassified subsequently to the statement of profit or loss:</i> | | | | | | |
| | Remeasurement of defined benefit obligation | 11 | (8) | (15) | 18 | 2 | ^ |
| | Income tax impact | (3) | 2 | 4 | (5) | (1) | ^ |
| | <i>Items that will be reclassified subsequently to profit or loss:</i> | | | | | | |
| | Exchange differences on translating the financial statements of foreign operation | ^ | 2 | 5 | (2) | (0) | (1) |
| | Total Other Comprehensive Income/(Loss) for the period/year (net of tax) | 8 | (4) | (6) | 11 | 1 | (1) |
| 7 | Total comprehensive income for the period/year (5+6) | 507 | 444 | 290 | 1,281 | 891 | 1,378 |
| 8 | Paid-up equity share capital (Face value of ₹ 2 each) | 478 | 478 | 444 | 478 | 444 | 444 |
| 9 | Other equity | | | | | | 9,094 |
| 10 | Earning per equity share (face value ₹ 2 each)* | | | | | | |
| | (a) Basic (in ₹) | 2.09 | 1.88 | 1.34 | 5.38 | 4.02 | 6.22 |
| | (b) Diluted (in ₹) | 2.07 | 1.86 | 1.33 | 5.33 | 3.99 | 6.17 |

*Earnings per share is not annualised for quarter ended and nine months ended.

See accompanying notes to the Standalone financial results



Indegene Limited (formerly Indegene Private Limited)

CIN No. U73100KA1998PLC102040

Notes to the Statement of Standalone Financial Results for quarter and nine months ended 31 December 2024

(All amounts in ₹ millions, except share data and where otherwise stated)

1. The above Standalone Financial Results of the Company have been prepared in accordance with Indian Accounting Standards ("Ind AS") 34 - Interim Financial Reporting, recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. ("the regulations"). Due to rounding off, the numbers presented throughout may not add up precisely to the totals. "^" in the financial information denote amounts less than ₹ 0.50 million.
2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 30 January 2025. The statutory auditors have performed a limited review of the Standalone Financial Results for the quarter and nine months ended 31 December 2024 and have issued an unmodified review report on the same.
3. The Standalone Financial Results for the quarter and nine months ended 31 December 2024, are available on the National Stock Exchange of India Limited (URL: www.nseindia.com), the BSE Limited website (URL: www.bseindia.com) and on the Company's website (URL: www.indegene.com/investor-relations).
4. During the nine months ended 31 December 2024, the Company has completed Initial Public Offer (IPO) of 40,766,550 equity shares of face value of ₹2 each at an issue price of ₹452 per share, comprising fresh issue of 16,833,818 shares aggregating to ₹7,600 and offer for sale of 23,932,732 shares by selling shareholders aggregating to ₹10,818. The Equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) on 13 May 2024. The Company was not mandatorily required to prepare and publish results for the quarter and nine months ended 31 December 2023 in accordance with the regulations.
5. The Company publishes this Standalone Financial Results along with the Consolidated Financial Results. In accordance with Ind AS 108, Operating Segments, the Company has disclosed the segment information in the Consolidated Financial Results.
6. During the quarter ended 31 December 2024, the Board of Directors approved the sale of the Company's Branch in United Kingdom ('UK') to its wholly owned subsidiary Indegene Healthcare UK Limited for a consideration of GBP 931,923 (₹100 million) computed at book value of the net assets to be transferred. Transaction is expected to be completed before 31 March 2025.

By Order of the Board of
INDEGENE LIMITED
(formerly INDEGENE PRIVATE LIMITED)



Manish Gupta
Chief Executive Officer and Executive Director

Bengaluru
30 January 2025

Date:- January 30,2025

The Declaration by CFO regarding audit report with unmodified opinion

I, Suhas Prabhu, Chief Financial Officer of the Company, hereby declare, that the Company's Statutory Auditors B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181), Chartered Accountants, have submitted an unmodified opinion / unqualified opinion on the unaudited Financial Results for the quarter ended 31st December 2024.

For Indegene Limited
(Formerly Indegene Private Limited)



Suhas Prabhu
Chief Financial Officer

indegene[®]

Registered office

Indegene Limited (Formerly Indegene Private Limited),
Third Floor, Aspen G-4 Block, Manyata Embassy Business
Park (SEZ), Outer Ring Road, Nagawara,
Bengaluru- 560 045, Karnataka, India

Phone : +91 80 4674 4567, +91 80 4644 7777
www.indegene.com

CIN: U73100KA1998PLC102040